呼吸道合胞病毒的治疗药物研发进展.PDF

现代药物与临床 Drugs Clinic 第 33 卷 第 2 期 2018 年 2 月 ·433 · • 综 述 • 呼吸道合胞病毒的治疗药物研发进展 潘永刚，刘晓志，高 健，王志明* 华北制药集团新药研究开发有限责任公司 抗体药物研制国家重点实验室，河北 石家庄 050015 摘 要：呼吸道合胞病毒（RSV ）是婴幼儿、老年人和免疫功能低下者诱发下呼吸道感染的主要原因。RSV 引起严重的呼 吸系统疾病，与长期喘息和后期哮喘风险增加有关。虽然 RSV 疫苗的开发已经有 50 多年，仍然没有批准上市的疫苗，对于 预防和治疗RSV 感染的疫苗和有效治疗药物尚未满足临床需求。帕利珠单抗和利巴韦林目前可用于RSV 感染的预防和治疗， 但不完全有效。因此需要针对 RSV 的预防和治疗提出新的疗法，用于满足临床医疗需求。近 10 年来，新抗病毒药物和单克 隆抗体的研发，已经显示出对RSV 治疗的临床应用前景，并且可能在未来几年陆续上市。尽管 RSV 融合蛋白（F 蛋白）已 成为小分子抑制剂和单克隆抗体最受欢迎的靶点，但靶向病毒其他蛋白质的新方法也得到了发展。同时针对逃逸株，可能会 采用联合用药，用于 RSV 病毒的治疗。对处于不同临床研发阶段的抗 RSV 病毒药物和单克隆抗体进行了综述。 关键词：呼吸道合胞病毒；单克隆抗体；帕利珠单抗；利巴韦林 中图分类号：R974 文献标志码：A 文章编号：1674 - 5515(2018)02 - 0433 - 06 DOI: 10.7501/j.issn.1674-5515.2018.02.050 Research progress on drugs in treatment of respiratory syncytial virus PAN Yong-gang, LIU Xiao-zhi, GAO Jian, WANG Zhi-ming State Key Laboratory of Antibody Research and Development; New Drug Research and Development Company Ltd., North China Pharmaceutical Corporation, Shijiazhuang 050015, China Abstract: Respiratory syncytial virus (RSV) is the major cause inducing lower respiratory tract infection for infants, the elderly, and immunocompromised persons. Respiratory diseases caused by RSV are associated with long-term breath and an increased risk of later asthma. Although the development of RSV vaccine has been for 50 years, there is still no approved vaccine for the prevention and treatment of RSV infection. The vaccine and effective drugs in treatment of RSV infection has not meet clinical needs. Palivizumab and ribavirin are currently the only available in the prevention and treatment of RSV infection, but not completely effective. Therefore it is necessary for the prevention and treatment of RSV new therapies to meet the clinical